Literature DB >> 33834412

"Novel Psychopharmacology for Depressive Disorders".

Michele Fornaro1,2, Domenico De Berardis3,4, Annalisa Anastasia3, Andrea Fusco5.   

Abstract

Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.

Entities:  

Keywords:  Esketamine; Ketamine; Major depressive disorder; Novel antidepressant; Treatment resistance

Mesh：

Substances：

Year:  2021        PMID： 33834412     DOI： 10.1007/978-981-33-6044-0_22

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  63 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  The STAR*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression.

Authors:  H Edmund Pigott
Journal:  Can J Psychiatry       Date:  2015-01       Impact factor: 4.356

Review 4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

5.  Suicide in major depression.

Authors:  E T Isometsä; M M Henriksson; H M Aro; M E Heikkinen; K I Kuoppasalmi; J K Lönnqvist
Journal:  Am J Psychiatry       Date:  1994-04       Impact factor: 18.112

6.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

7.  Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

Authors:  A John Rush; Madhukar H Trivedi; Jonathan W Stewart; Andrew A Nierenberg; Maurizio Fava; Benji T Kurian; Diane Warden; David W Morris; James F Luther; Mustafa M Husain; Ian A Cook; Richard C Shelton; Ira M Lesser; Susan G Kornstein; Stephen R Wisniewski
Journal:  Am J Psychiatry       Date:  2011-05-02       Impact factor: 18.112

Review 8.  The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions.

Authors:  Michele Fornaro; Marco Solmi; Nicola Veronese; Domenico De Berardis; Elisabetta Filomena Buonaguro; Carmine Tomasetti; Giampaolo Perna; Antonio Preti; Mauro Giovanni Carta
Journal:  Int Rev Psychiatry       Date:  2017-07-06

Review 9.  The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, and clinical implications.

Authors:  Michele Fornaro; Annalisa Anastasia; Stefano Novello; Andrea Fusco; Riccardo Pariano; Domenico De Berardis; Marco Solmi; Nicola Veronese; Brendon Stubbs; Eduard Vieta; Michael Berk; Andrea de Bartolomeis; André F Carvalho
Journal:  Pharmacol Res       Date:  2018-10-29       Impact factor: 7.658

Review 10.  Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis.

Authors:  Klaus Munkholm; Asger Sand Paludan-Müller; Kim Boesen
Journal:  BMJ Open       Date:  2019-06-27       Impact factor: 2.692
View more
  2 in total

1.  Suicide versus Accidental Death by Autoerotic Asphyxiation in a Patient Receiving Intravenous Ketamine for Depression.

Authors:  Jeremy Weleff; Kelly Bryant; Alexsandra Kovacevich; Brian S Barnett
Journal:  Case Rep Psychiatry       Date:  2022-04-26

2.  Selective Serotonin Reuptake Inhibitors for the Prevention of Post-Stroke Depression: A Systematic Review and Meta-Analysis.

Authors:  Daniel Richter; Jeyanthan Charles James; Andreas Ebert; Aristeidis H Katsanos; Lisa Mazul-Wach; Quirin Ruland; Ralf Gold; Georg Juckel; Christos Krogias
Journal:  J Clin Med       Date:  2021-12-16       Impact factor: 4.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.